key: cord-0833854-1u3qkkjv
authors: Bolze, Alexandre; Neveux, Iva; Schiabor Barrett, Kelly M.; White, Simon; Isaksson, Magnus; Dabe, Shaun; Lee, William; Grzymski, Joseph J.; Washington, Nicole L.; Cirulli, Elizabeth T.
title: HLA-A*03:01 is associated with increased risk of fever, chills, and stronger side effects from Pfizer-BioNTech COVID-19 vaccination
date: 2022-01-01
journal: HGG Adv
DOI: 10.1016/j.xhgg.2021.100084
sha: 6d4dc0449a1ee5751f5e37f8d537abf3cfaa71d4
doc_id: 833854
cord_uid: 1u3qkkjv

COVID-19 vaccines are safe and highly effective, but some individuals experience unpleasant reactions to vaccination. As the majority of adults in the US have received a COVID-19 vaccine this year, there is an unprecedented opportunity to study the genetics of reactions to vaccination via surveys of individuals who are already part of genetic research studies. Here, we have queried 17,440 participants in the Helix DNA Discovery Project and Healthy Nevada Project about their reactions to COVID-19 vaccination. Our GWAS identifies an association between severe difficulties with daily routine after vaccination and HLA-A*03:01. This association was statistically significant only for those who received the Pfizer-BioNTech vaccine (BNT162b2; n=3,694; p=4.70E-11; OR=2.07 (95%CI 1.67-2.56)), and showed a smaller effect size in those who received the Moderna vaccine (mRNA-1273; n=3,610; p=0.005; OR=1.32 (95%CI 1.09-1.59)). In Pfizer-BioNTech recipients, HLA-A*03:01 was associated with a two-fold increase in risk of self-reported severe difficulties with daily routine following vaccination. The effect was consistent across ages, sexes, and whether the person had previously had a COVID-19 infection. The reactions experienced by HLA-A*03:01 carriers were driven by associations with chills, fever, fatigue, and in general feeling unwell.

Pfizer-BioNTech recipients, HLA-A*03:01 was associated with a two-fold increase in risk of self-30 reported severe difficulties with daily routine following vaccination. The effect was consistent 31 across ages, sexes, and whether the person had previously had a COVID-19 infection. The 32

Introduction 36

Less than one year after the first publication of a SARS-CoV-2 sequence, COVID-19 vaccines 37 were developed, clinically tested and authorized to be administered in the general population. 38

Within months, hundreds of millions of adults worldwide were vaccinated, and rates of 39 hospitalization among vaccinated individuals dropped precipitously; potential side effects were 40 mild 1 COVID-19 vaccination. The aim of this study is therefore to identify factors associated with 51 reactions following COVID-19 vaccination. Similarly to our hypothesis that genetic factors play 52 a role in the severity of COVID-19 disease 5,6 , we hypothesized that genetic factors help explain 53 differences in reactions following COVID-19 vaccination. To test our hypothesis, we 54 administered online surveys to 17,440 participants from the Helix DNA Discovery project and 55 the Healthy Nevada Project asking about their vaccination status and their reactions following 56 the vaccine. These surveys included questions about 4 local and 20 systemic symptoms, as 57 well as the overall severity of the reaction and its impact on daily routine in the days following 58 vaccination. These participants were previously sequenced with Helix Exome+ assay, which 59 allowed us to perform rare and common variant genetic associations 7 . 60 61 J o u r n a l P r e -p r o o f To test our hypothesis that genetic variation drives some of the differences seen in vaccine 145 reaction, we performed a genome-wide association study (GWAS) using a phenotype of 146 extreme or severe difficulties with daily routine (1,709 cases) compared to no or mild difficulties 147 (6,203 controls). Individuals reporting moderate difficulties were excluded from the GWAS 148 (Table 1 ). Our analysis of 12,602,603 SNPs identified 188 genome-wide significant variants on 149 chromosome 6 (p<5e-8; Figure 1 , Figure S2 ). The lead SNP was rs144943243 / We next analyzed imputed HLA types against the phenotype to identify whether a specific HLA 155 type was associated with the GWAS signal. We identified a significant association with HLA-156 A*03:01 (p=5.00E-11), which had a MAF of 15% in the European genetic ancestry subset of our 157 cohort. The distribution of HLA-A*03:01 across the globe is shown in Figure S3 Figure S4 ). However, our analyses beyond European (p=5.00E-11, 172 OR=1.6) and Hispanic (p=2.93E-04, OR=2.7) genetic ancestries were underpowered to identify 173 associations (Table S1 ). We also observed that most of the effect seems to occur at the second 174 dose for two-dose vaccines ( Figure S5 ), and that severe difficulties subsided within 2 days for 175 66% of those who experienced severe difficulties ( Figure S6) we also analyzed the reactions in Moderna recipients by restricting the cases to only those who 185 reported extreme difficulties (n=473) and the controls to those who reported no difficulties 186 (n=1,425). The confidence intervals for the odds ratio from this analysis overlapped those from 187 the analysis of Pfizer recipients, though the p-value lacked statistical significance (p=0.008, 188 OR=1.49 (95% CI 1.11-1.99)). The sample sizes for those who received J&J or other 189 vaccinations were too low to clearly assess an association. Detailed counts of reaction severity 190 split by genetic ancestry, HLA-A*03:01 status, and vaccine type are reported in Table S1 . also be as simple as the fact that the higher prevalence of vaccine reactions in Moderna 250 recipients make the signal harder to identify in that subgroup (Figure 2, Figure S1 , Figure S5 ). 251

Replication of the result in other cohorts, with results broken down by COVID-19 vaccine types, 252 will be informative to hypothesize further about potential mechanisms leading to these reactions. 253 254 255

One limitation of our study is that the HLA calls were imputed by HIBAG as opposed to being 256 directly genotyped 12 . These imputed values are affected by ancestry, LD patterns, and SNP 257 quality, and it is expected that a portion of the imputed HLA types are incorrect. For this reason, 258 it is also not certain that HLA-A*03:01 is the causal allele. Of note, the lowest p-value we obtained 259 for the main phenotype for Pfizer recipients was chr6:29945053:T:C / rs2571381 (p=1.16E-12); 260 and the lowest p-value obtained for any phenotype was for fever in Pfizer recipients at Researchers who would like to obtain the raw genotype data related to this study will be presented 317 with a data user agreement which requires that no participants will be re-identified and no data 318 will be shared between individuals or uploaded onto public domains. The IHI encourages and 319 collaborates with scientific researchers on an individual basis. Examples of restrictions that will 320 be considered in requests to data access include but are not limited to (1) whether the request 321 comes from an academic institution in good standing and will collaborate with our team to protect 322 the privacy of the participants and the security of the data requested, (2) type and amount of data 323 

Reactogenicity Following Receipt of 332 mRNA-Based COVID-19 Vaccines

Safety and Efficacy of the BNT162b2 335 mRNA Covid-19 Vaccine

Efficacy and Safety of the mRNA

CoV-2 Vaccine

Vaccine side-effects and SARS-CoV-2 infection after 341 vaccination in users of the COVID Symptom Study app in the UK: a prospective observational 342 study

Mapping the human genetic architecture of 344 COVID-19

A Global Effort to Define 346 the Human Genetics of Protective Immunity to SARS-CoV-2 Infection

Helix's Exome+ Performance White Paper

Introducing the Helix DNA Discovery Project

Population Health Genetic Screening for Tier 1 351 Inherited Diseases in Northern Nevada: 90% of At-Risk Carriers are Missed

Genome-wide rare variant analysis for 354 thousands of phenotypes in over 70,000 exomes from two cohorts

HIBAG--HLA genotype imputation with attribute bagging

Computationally efficient 361 whole genome regression for quantitative and binary traits

S Vaccine against Covid-19

Allele frequency net database (AFND) 2020 update: gold-standard data classification, open 368 access genotype data and new query tools

Whole genome sequencing 371 identifies multiple loci for critical illness caused by COVID-19

The Association Between

Oxcarbazepine-induced Maculopapular Eruption in the Uighur Chinese Population

HLA-A*03 and response to immune checkpoint blockade in 378 cancer: an epidemiological biomarker study

BNT162b2 vaccine induces neutralizing 381 antibodies and poly-specific T cells in humans

Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

Global Biobank Engine: enabling genotype-phenotype browsing for biobank 388 summary statistics

HLA haplotypes associated with hemochromatosis 391 mutations in the Spanish population

-2 human T cell epitopes: Adaptive immune response against COVID-19

GWAS 396 identifying HLA-DPB1 gene variants associated with responsiveness to hepatitis B virus 397 vaccination in Koreans: Independent association of HLA-DPB1*04:02 possessing rs1042169 G 398 -rs9277355 C -rs9277356 A

A 400 genome-wide association study of hepatitis B vaccine response in an Indonesian population 401 reveals multiple independent risk variants in the HLA region

Threatening Infections Due to Live-Attenuated Vaccines: Early Manifestations of Inborn Errors 404 of Immunity

Severe 407 Mycobacterium bovis BCG infections in a large series of novel IL-12 receptor β1 deficient 408 patients and evidence for the existence of partial IL-12 receptor β1 deficiency

Self-Reported Symptoms of COVID-412 19, Including Symptoms Most Predictive of SARS-CoV-2 Infection, Are Heritable

Will GWAS eventually allow 415 the identification of genomic biomarkers for COVID-19 severity and mortality?

X-linked recessive TLR7 419 deficiency in ~1% of men under 60 years old with life-threatening COVID-19

Life-Threatening COVID-422 19: Defective Interferons Unleash Excessive Inflammation

Effectiveness of mRNA

BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a 426 retrospective cohort study

N with positive COVID-19 test before vaccination (%)

-Extreme difficulties / unable to perform daily routine 3-Severe difficulties with daily routine 2-Moderate difficulties with daily routine 1-Mild difficulties with daily routine 0-No difficulties